Author information
Abstract
Patients with multiple sclerosis have long turned to complementary therapies to manage symptoms that licensed products can only partially control. Around half of patients with multiple sclerosis admit to previous or current cannabis use for medicinal purposes and would endorse legalisation. Despite many governments worldwide relaxing regulations around medicinal cannabis, there remain many unanswered questions as to how clinicians should prescribe or recommend products, and access to pharmaceutical-grade products remains highly restricted. Here we address what adult neurologists need to know about cannabis and its use in multiple sclerosis.
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
KEYWORDS: cannabis, multiple sclerosis, pain, spasticity
- PMID: 31201234
- DOI: 10.1136/practneurol-2018-002137
Conflict of interest statement
Competing interests: GI has accepted payments and honorariums for speaking, travel and advisory boards from Merck, Genzyme and Biogen. ORP has accepted payments and honorariums for speaking, travel and advisory boards from Merck, Genzyme, Roche, Biogen, Novartis and Teva.
